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Abstract
The involvement of immunity in the pathogenesis of schizophrenia and related 
psychoses was suspected a century ago but was shadowed by the dopaminergic 
hypothesis after the discovery of antipsychotics. We currently know that this latter 
theory has many limits and cannot account for the wide variety of psychotic condi-
tions. The immune-inflammatory theory is now one of the most promising axes of 
research in terms of pathogenesis of several mental health conditions. Immunity 
and inflammation play a role at least in a subgroup of patients with psychosis. The 
immune system is complex with a variety of components and mediators that can all 
have effects on the brain and thus mediate psychiatric symptoms. In this chapter 
we will explore the scientific evidence of the role of immune system in patho-
physiology of psychosis. The sections of this chapter will discuss the role of innate 
system components (cytokines, microglia, inflammation.), the role of adaptive 
system (lymphocytes and antibodies) with a section focusing on auto-immunity 
and particularly antineuronal antibodies. Finally we will discuss how this research 
can impact patients management and elaborate recommendations for future 
research.
Keywords: schizophrenia, psychosis, inflammation, auto-immunity, antineuronal 
antibodies, pathophysiology
1. Introduction
The role of the immune system in mental disorders was suspected since the last 
century [1]. Then, the discovery of efficient antipsychotic drugs led researches to 
focus on the dopaminergic theory undermining the first immunological findings. 
Nonetheless, this theory has many limits and cannot account for the wide diversity 
of clinical presentations in patients with psychosis. In the last decades, there was a 
breakthrough in technical investigations that led to significant improvement of our 
understanding of the immune system functioning and the immune theory became a 
promising axis of research.
The immune system has a complex organization with an innate system (mediated 
by macrophages, neutrophils and cytokines) and an adaptive system which is antigen 
specific (mediated by T and B lymphocytes and antibodies secreted by B lymphocytes).
Many researchers have found immunological abnormalities in patients with 
psychosis involving both the innate and the adaptive system [2]. All immune 
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system components can have effects on the brain cells and thus they can produce 
psychiatric symptoms [2]. Increase in inflammation markers was detected in 
schizophrenia [3]. Early life and prenatal exposition to infections predicted adult 
schizophrenia [4, 5]. High rates of auto-antibodies were reported in psychiatric 
conditions especially antineuronal antibodies [6–8]. There are genetic findings 
that also consolidate these theories [9]. All these findings allow to conclude that 
immunity plays a role in pathophysiology of psychosis at least in a subgroup of 
patients. There are already trials using treatments targeting the immune system 
with encouraging results [10]. This axis of research can have an impact on the 
understanding and treatment of schizophrenia and related psychoses and allow a 
new era of immuno-psychiatry.
2.  Evidence of involvement of immune system in pathogenesis of 
psychosis
2.1 Role of inflammation and innate immune system
Inflammation and innate system are the first line response, nonspecific to an 
antigen, when an infection occurs. It involves neutrophils, macrophages, microg-
lia and secretion of acute-phase proteins like inflammatory cytokines. There is 
evidence for inflammation dysfunction in psychosis. Interleukins and C Reactive 
Protein (CRP) increase in patients with psychosis [11, 12]. An increase in the 
production of proinflammatory cytokines such as Interleukin 6 (IL-6) was detected 
in patients with schizophrenia [13] and patients at high risk for psychosis [14] and 
predicted development of adult schizophrenia when detected in children [4]. This 
increase in IL-6 was also found in the cerebrospinal fluid [15] in schizophrenia 
patients. A meta-analysis showed that pro-inflammatory cytokines increased in 
acute psychosis phase either during a first episode or during a relapse, and normal-
ized after antipsychotic treatment [16].Thus, these markers could be used to detect 
acute psychosis and predict relapses. Peripheral inflammation can also affect the 
brain [17]. In fact, inflammation can activate endothelial cells in brain vessels and 
increase their permeability to immunological cells [18]. Moreover, inflammation 
that begins in periphery can reach the brain, probably through vagus nerve signals 
[17] and can activate microglia. Microglia is an essential component of central ner-
vous system and has a hemopoietic origin [19]. Inflammation can activate microglia 
which in turn can release cytokines in the brain. Microglia also interacts with 
lymphocytes and can play a role of antigen presenting cell. This is consistent with 
the “microglia activation hypothesis” [20] that emphasizes the role of cytokines and 
free radicals produced by the activated microglia in pathophysiology of psychosis. 
Those substances can cause white matter and neurogenesis abnormalities and 
neuronal alterations associated with psychosis. Cytokines can also amplify the oxi-
dative stress via toxic nitric oxide, which in turn, activates the hypothalamic–pitu-
itary–adrenal axis [17]. This leads to the activation of the corticosteroid system that 
releases stress hormones such as cortisol [17, 21]. All these inflammatory processes 
could result in mood and cognition disturbances in humans [18, 22] through direct 
effect on the brain and through the cortisol secretion alterations. Corticosteroid 
levels alterations are known to induce affective and behavioral disturbances. 
The activation of corticosteroid system by cytokines following an inflammatory 
immune response has already been demonstrated in major depressive disorder and 
could also be part of the pathophysiology of psychosis [17, 18, 22].
Schizophrenia has been associated with prenatal infections [5] and with child-
hood central nervous system infections [4]. These findings suggest a common 
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underlying pathway between schizophrenia and infectious conditions involving 
mainly inflammatory immune response [21].
2.2 Role of lymphocytes and adaptive system
The adaptive system represents the second line antigen-specific immune 
response. It involves lymphocytes B and T and antibodies secreted by lymphocytes 
B. It also allows to keep a memory of past infections.
Findings from experimental studies found abnormalities in lymphocytes 
function and number in patients with schizophrenia, particularly T-cells [12, 22]. 
Interleukin 2 (Il-2) is involved in immune response regulation. T cells of schizo-
phrenia patients produce reduced amounts of Il-2 in vitro [23], and schizophrenia 
was associated with more activated lymphocytes, expressing CD56, compared to 
controls [24], especially in acute relapses, with changes in the ratio CD8/CD4 cells 
[22]. Baseline lymphopenia can be associated with severe psychosis and predict 
poor outcome and poor treatment response [25]. These findings are consistent with 
The “macrophage-T-lymphocyte theory” postulating that cytokines produced by 
activated lymphocytes T and macrophages play a main role in pathophysiology of 
schizophrenia [26]. In fact, CD4 T-lymphocytes secrete cytokines such as IFN-γ 
and IL-12 which can activate CD56-lymphocytes that secrete TNF-α and IFN-γ. 
Pro-inflammatory cytokines are associated with schizophrenia as was shown in the 
previous section [16]. A decrease in CD19 B-lymphocytes count was demonstrated 
in patients treated with adjunctive celecoxib [27] and this was associated with nega-
tive symptoms improvement. Post-mortem studies reported evidence of microglia 
activation [28, 29] and increased number of lymphocytes [30] in schizophrenia. 
Most studies focused on blood cells count [22], while there can also be changes in 
cerebrospinal fluid as demonstrated by many authors [24, 31, 32].
2.3 Role of auto-immunity and antineuronal antibodies
The involvement of autoimmunity in psychosis was suspected about a century 
ago [1, 33]. There is evidence for the role of auto-immune antibodies, in the patho-
genesis of psychiatric disorders in general and in psychosis in particular [7, 33]. 
Psychotic and auto-immune conditions share many clinical and biological features 
like a young age onset [1, 34, 35], stress-triggered [6, 36], they have chronic course 
with relapses and possible residual symptoms [6, 34]. Besides, psychosis is often 
associated with auto-immune conditions [35] and high levels of auto-immune 
antibodies were found in patients with psychosis (e.g. antibodies anti-gliadin and 
anti-casein) [7, 37] and particularly antineuronal antibodies [2, 8, 38]. Antineuronal 
antibodies can target cell surface components, such as the N-Methyl D Aspartate 
(NMDA) receptor, or they can target intra-cellular nuclear or cytoplasmic antigens.
The most studied antineuronal antibodies in the literature are cell surface anti-
bodies anti-NMDA [38]. Patients with anti-NMDA antibodies often present with 
predominant psychotic symptoms and subsequently develop other neurological 
symptoms [39]. This is called NMDA encephalitis and can be treated using immu-
notherapy and removal of auto-antibodies [40]. Some patients have anti-NMDA 
and mild psychotic symptoms but have no neurological symptoms of encephalitis. 
Authors have suggested the concept of “ auto-immune psychosis ” [41, 42] to 
describe this entity.
There are many arguments for NMDA receptor hypofunction in schizophrenia 
[2, 38]. The administration of ketamine and phencyclidine, which are NMDA 
receptor blockers, is known to cause clinical [43, 44] and physiological symptoms 
[45] similar to schizophrenia. Glutamate and glycine are necessary for NMDA 
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Figure 1. 
Early life interactions resulting in susceptibility to psychosis.
receptor activation and they have decreased levels in schizophrenia [38, 46, 47]. 
Psychosis is also associated with abnormal D-amino acids levels (including D-serine 
and D-alanine) [48, 49] which are modulators of neuronal activity [50] and act as 
co-agonists of NMDA receptor at the Glycine Modulatory Site [38, 46]. There is also 
an increase in antagonist agents of NMDA receptor in schizophrenia [51]. These 
findings were used in developing treatment trials for psychosis by augmenting 
NMDA receptor function [38, 41].
Antineuronal antibodies can also target intracellular antigens such as 
Antineuronal Nuclear Autoantibodies (ANNA) (called anti-Hu and anti-Ri) and 
Anti cytoplasm of Purkinje cells Antibodies (PCA) (called anti-Yo). Those antibod-
ies have been classically associated with paraneoplastic syndromes [52, 53] but they 
were also found in persons with neurological or psychiatric conditions with no 
associated tumor [8]. For example, these antibodies were found in association with 
neurological diseases [54], with auto-immune diseases [55], with neuropsychiatry 
symptoms of neurolupus [56], with autism [57, 58] and with obsessive compulsive 
disorder [59, 60]. A study found ANNA antibodies were significantly higher in 
schizophrenia and bipolar disorder patients compared to healthy controls [8] 
with no tumor detected after 5 years follow up. In this study, PCA antibodies were 
associated with the presence of affective symptoms. Most authors are now focusing 
on anti-NMDA antibodies but future studies should address these antinuclear and 
cytoplasmic antibodies.
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2.4 Genetic findings
Genome Wide Association Studies (GWAS) found an association between 
schizophrenia and genes that are related to immune system cells [61]. Another 
GWAS showed that a single nucleotide polymorphism in major histocompatibility 
complex on chromosome 6 was associated with schizophrenia [62]. This region of 
chromosome 6 includes genes expressing proteins involved in pro-inflammatory 
cytokines. A genetic association was also found between schizophrenia and multiple 
sclerosis, an immune mediated disease [63].
Figure 2. 
Simplified diagram of possible immune interactions resulting in psychotic symptoms. Lc, lymphocyte; NMDA, 
N-methyl D-aspartate receptor; ANNA, antinuclear neuronal antibodies; PCA, anti Purkinje cell cytoplasm 
antibodies.
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As we previously discussed, NMDA-receptor downregulation is associated with 
schizophrenia. A meta-analysis showed that there is hypoexpression of the mRNA 
of a subunit of NMDA receptor called GluN1 [64] in schizophrenia. Besides, the 
expression and activity of DAAO, an enzyme that catabolizes D-amino acids which 
act like agonists of NMDA receptor, are increased and DAAO gene is considered as 
risk gene for schizophrenia [65].
During the early life and prenatal development, the association between genetic 
susceptibility and early infections can affect immunological pathways illustrating 
the gene-infection interaction (Figure 1).
2.5 Summary of immune systems interactions leading to psychotic symptoms
In the previous sections, we presented evidence for the implication of innate 
and adaptive system in psychosis pathogenesis. This separation between innate and 
adaptive systems is schematic and is usually used for its clarity. In reality, all these 
components interact with each other in order to perform an adequate immunologi-
cal response to infection (Figure 2). How do all these systems interact and lead to 
psychosis symptoms? In a classic immune response to an infection, innate system is 
the first actor through macrophages activation and cytokines secretion. Then, T and 
B-lymphocytes are activated and also produce inflammatory cytokines. On the one 
hand, inflammation activates microglia in the brain which in turn secretes inflam-
matory cytokines. This environment of inflammation and oxidative stress could 
lead to hypothalamic activation and then corticosteroid system activation with 
release of stress hormones. Oxidative stress within the brain and stress hormones 
are known to account for mood and behavioral disturbances. On the other hand, 
B-lymphocytes can secrete auto-antibodies that react with neuronal brain cells. 
These antineuronal antibodies can target cell surface (such as anti-NMDA) or target 
intracellular antigens (such as ANNA and PCA). All these auto-antibodies were 
associated in the literature with psychiatric conditions.
3. Treatment implications
Antipsychotics, either first or second generation, were the only treatments 
used in patients with psychosis for decades. Nonetheless, they have many limita-
tions. They are quite effective on positive symptoms but they failed at treating 
negative and cognitive dimensions or global functioning [66]. Moreover, there is a 
significant rate of treatment resistance of nearly 30% [67]. Besides, they can induce 
severe neurological, metabolic or hematologic side effects [68]. The rationale of 
these treatments is based on the dopaminergic theory which cannot account for all 
aspects and symptoms of psychosis. Thus, researchers are looking for treatment 
alternatives.
Given the substancial evidence of immune dysfunction in psychosis, scientists 
have tried medications acting on the immune system. There have been many trials 
with anti-inflammatory medications combined with antipsychotics [10] using aspi-
rin [69, 70], celecoxib [27, 71, 72] and N-acetyl-Cystein [73, 74] with encouraging 
results (Table 1). Celecoxib [27] and N-acetylcysteine [73, 74] were associated with 
negative symptoms improvement. Meta-analyses about adjunctive minocycline, a 
tetracycline antibiotic with anti-inflammatory properties, found global improve-
ment in PANSS total score [76] and cognitive function [77, 80]. Two meta-analyses 
assessed trials using other molecules with anti-inflammatory and neuroprotec-
tive properties such as eicosapentaenoic acid, pregnonolone, estrogens, Selective 
Estrogen Receptor Modulators [77] and statins [79]. Only eicosapentaenoic acid 
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was not associated with significant clinical improvement. Results reported global 
improvement in total PANNSS scores on all other agents and cognitive function 
improvement on pregnonolone and negative symptoms improvement on simvasta-
tine. A pilot trial demonstrated improvement of cognitive function on recombinant 
human erythropoietin [78]. Despite limitations, like study sample size, and despite 
the presence of some negative results [70, 72], authors reported promising results. 
There was an overall good tolerance.
Some biological agents can act as inflammatory response modulators, such as 
monoclonal antibodies and mesenchymal stem cells, and were studied in recent 
trials in neurological and psychiatric disorders like autism and schizophrenia [85]. 
Trials using adjunctive monoclonal antibodies, like tocilizumab and canakinumab, 
in psychosis reported improvement in negative [80] or positive symptoms [86] or 
no significant improvement [81].
There is another axis of research based on NMDA receptor augmenting strate-
gies based on the increase of agonists of this receptor or decrease of antagonists. 
There were tens of placebo controlled trials using agonists of Glycerine Modulatory 
Site in NMDA receptor [38] such as glycine or D-amino acids. The results were 
mixed [38, 82]. Methodological bias and differences in the used molecules can 
account for the variability of the results. A meta-analysis did not find improve-
ment in cognitive function using glutamate positive modulators in schizophrenia 
[83]. However a pilot study showed an improvement in negative symptoms using 
D-serine, which is an agonist of NMDA receptor, in teenagers with high risk of 
psychosis [84]. Thus, it could be useful to use NMDA augmenting in prevention for 
early psychosis stages (Table 1).
Clinical trials are now focusing on anti-inflammatory strategies and NMDA aug-
menting. It would be useful to widen our perspective and consider other therapeutic 
options. For example, we could consider treatments inspired from well-established 
auto-immune conditions like removal of antibodies or immunosuppression. Many 
of the trials mentioned above still suffer from lack of data. There are limitations 
to the generalization and clinical application of these therapies. There are con-
founding factors like the type of antipsychotic drug used in combination, patients 
compliance, inclusion criteria, illness stage, medical history and other factors that 
Adjunctive therapy Main trials results
N-Acetyl-Cystein PANSS improv [73]; Neg symp improv [74];
Aspirin PANSS improv [69, 70]
Celecoxib PANSS improv [71, 75]; Neg symp improv [27]; No signif improv [72]
Minocycline PANSS improv [76]
Pregnenolone PANSS improv, Cognitive improv (5 trials) [77]
Estrogen PANSS improv (8 trials) [77]
Erythropoietin Cognitive improv [78]
Eicosapentaenoic acid No sig improv (20 trials) [77]
Statins PANSS improv [79] with negative symp improv on simvastatine
Tocilizimab Negative symptoms improv [80]; no signif improv [81]
NMDA modulators No cog improv [82, 83]; negative symptoms improv in UHR [84]
improv, improvement; no signif, no significant; PANSS improv, PANSS total score improvement; UHR, Ultra High 
Risk for psychosis.
Table 1. 
Main results of trials using adjunctive immunotherapy combined with antipsychotics.
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modulate immune response such as body mass, smoking status, or associated stress. 
All these factors need to be addressed and controlled in larger studies. However, 
despite these limitations, we can notice that there is accumulative evidence of the 
potential of anti-inflammatory and immunotherapy strategies in treating patients 
with psychosis. We need a better definition of patients subgroups and specific 
symptoms that could benefit from these therapies. A stratification of patients could 
be made using the immunological status and/or clinical dimensions.
4. Recommendations for future research
It is now clear that we should not limit our research and treatment strategies to 
antipsychotics. Immunological alterations seem to account for psychotic symptoms 
in a subgroup of patients. These patients can benefit from immunotherapy. The 
challenge is to better characterize this subgroup and define the features that predict 
a good response to immunotherapy. A stratification should be made using biological 
markers, clinical symptoms, response to antipsychotic treatments, disease stage 
etc. We could define an immune phenotype that predicts treatment response. It 
was used successfully in a trial about depression [87]. In this trial, patients who 
had baseline high levels of inflammatory mediators had significant improvement 
of depressive symptoms on infliximab which is an anti-inflammatory agent. This 
approach should be explored in psychosis.
Some clinical symptoms do not respond well to antipsychotics like the negative 
and cognitive dimensions [66]. These symptoms could benefit from other therapeu-
tic strategies. As mentioned above, many immunotherapy trials reported improve-
ment in negative or cognitive domains [27, 74, 76, 78, 79]. There are arguments 
that corroborate this theory: inflammation was associated with impairments in 
memory and learning [88] and in spatial memory [89]. There is still no established 
physiopathology accounting for immune therapies effects on negative and cogni-
tive symptoms but hypothetical mechanisms can be proposed. Inflammation and 
cytokines are associated with cognitive impairments [88, 89]. Inflammation is also 
incriminated in the genesis of negative symptoms and motivational deficits through 
the action of cytokines on basal ganglia and through decrease of neuronal activity 
in reward system [90]. Thus, anti-inflammatory drugs could improve cognitive 
symptoms by reducing inflammation.
All these clinical and biological features (i.e. negative and cognitive symptoms, 
inflammatory phenotype etc.) should be considered as endophenotypes related to 
psychosis and used to categorize and stratify patients in future trials. A subgroup 
of patients with schizophrenia could have immune alterations accounting for 
psychotic symptoms and would be more prone to respond to immune therapy. 
This subgroup could have some characteristics: prominent negative symptoms and 
cognitive dysfunction, poor response to conventional treatments, a specific immune 
phenotype characterized for example by elevated baseline inflammatory markers 
or increased lymphocytes number. The immune phenotype predicting therapeutic 
response has to be better specified in future studies (which markers? What are 
the specific sub-types of lymphocytes? Etc). The duration of illness can influence 
clinical presentation and treatment response. Some immunotherapies proved 
more effective when administered at an early stage of psychosis [84]. A staging of 
psychotic conditions should be considered, as for staging used in cancers, in some 
immune diseases, and bipolar disorder [91].
Antipsychotic treatment resistance is a challenge for scientists and causes disability 
and high personal and social burden. Those patients could benefit from new genera-
tion treatments like immunotherapy. Some immunological markers can predict severe 
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psychosis and poor treatment response on antipsychotics [14, 22, 25]. In the future, 
we could define precise immunological markers that may predict antipsychotic 
resistance and good response to immunotherapy.
The inflammatory status can differ between acute exacerbation phases and 
residual phases [16, 30]. Thus, inflammation markers could be used to predict 
and diagnose psychotic relapses or first episode psychoses in addition to clinical 
examination.
Multicenter large trials are needed with study of lymphocytes numbers and 
subtypes, cytokines types and with control of confounding factors. Dosage of 
anti-inflammatory treatments and interactions with antipsychotics should also be 
addressed. New strategies based on auto-immune model can broaden the therapeu-
tic arsenal.
A novel axis of research based on the “gut-brain theory” should be considered 
in future research. In this theory, the intestinal microbiota composition could play 
a role in many central nervous system diseases through a bidirectional pathway 
between gut and brain [92]. Mechanisms of this interplay probably involves neuro-
humoral communication, vagus nerve signals and tryptophan metabolism [75].
5. Conclusions
The role of immunity in the pathogenesis of psychosis is now established, at 
least in a subgroup of patients. The challenge is to determine solid criteria to recog-
nize this subgroup with possible benefit from immunotherapy. Another challenge is 
to develop efficient therapies based on immune system interactions with acceptable 
tolerance.
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